Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor

Pediatric Blood and Cancer

Volumn 59, Issue 3, 2012, Pages 499-505

  Ohshima, Junjiro ^a,b   Haruta, Masayuki ^a   Fujiwara, Yuiko ^a   Watanabe, Naoki ^a   Arai, Yasuhito ^c   Ariga, Tadashi ^b   Okita, Hajime ^d   Koshinaga, Tsugumichi ^d   Oue, Takaharu ^d   Hinotsu, Shiro ^d   Nakadate, Hisaya ^d   Horie, Hiroshi ^d   Fukuzawa, Masahiro ^d   Kaneko, Yasuhiko ^a,d  

^a SAITAMA CANCER CENTER   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d Japan Wilms Tumor Study Group JWiTS   (Japan)

Author keywords

Biomarkers; Methylation; RASSF1A; Wilms tumor

Indexed keywords

CASPASE 8; DCR2 PROTEIN; RAS ASSOCIATION DOMAIN FAMILY 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CHROMOSOME 16Q; CHROMOSOME 1P; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; EVENT FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GROUPS BY AGE; HETEROZYGOSITY LOSS; HOSPITALIZED CHILD; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; NEPHROBLASTOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD;

CHILD; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; HUMANS; MALE; PROGNOSIS; PROMOTER REGIONS, GENETIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; WILMS TUMOR;

EID: 84863860170     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24093     Document Type: Article

References (33)

1. Perlman EF, Grosfeld JL, Togasi K, et al. Pathology and genetics of tumours of the urinary system and male genital organs. In: Eble JN, Sauter G, Epstein JI, et al. editors. World Health Organization classification of tumours. Lyon: IARC Press; 2004.
2. Rivera MN, Haber DA. Wilms' tumour: Connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 2005; 5: 699-712.
3. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J Clin Oncol 2010; 28: 2625-2634.
4. Dome JS, Cotton CA, Perlman EJ, et al. Treatment of anaplastic histology Wilms tumor: Results from the fifth National Wilms Tumor Study. J Clin Oncol 2006; 24: 2352-2358.
5. Hamilton TE, Ritchey ML, Haase GM, et al. The management of synchronous bilateral Wilms tumor: A report from the National Wilms Tumor Study Group. Ann Surg 2011; 253: 1004-1010.
6. Malogolowkin M, Cotton CA, Green DM, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomysin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2008; 50: 236-241.
7. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: A report from the National Wilms Tumor Study Group. J Clin Oncol 2005; 23: 7312-7321.
8. Dome JS, Bockhold CA, Li SM, et al. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor. J Clin Oncol 2005; 23: 9138-9145.
9. Ghanem MA, van Steenbrugge GJ, Sudaryo MK, et al. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol 2003; 56: 107-113.
10. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer: From epigenetic silencing to functional characterization. Biochim Biophys Acta 2009; 1796: 114-128.
11. Pfeifers GP, Dammann R. Methylation of tumor suppressor gene RASSF1A in human tumors. Biochemistry 2005; 70: 576-583.
12. Sugawara W, Haruta M, Sasaki F, et al. Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma. Pediatr Blood Cancer 2007; 49: 240-249.
13. Honda S, Haruta M, Sugawara W, et al. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients. Int J Cancer 2008; 123: 1117-1125.
14. Haruta M, Matsumoto Y, Izumi H, et al. Combined BubR1 protein down-regulation and RASSF1A hypermethylation in Wilms tumors with diverse cytogenetic changes. Mol Carcinog 2008; 47: 660-666.
15. Wagner KJ, Cooper WN, Grundy RG, et al. Frequent RASSF1A tumor suppressor gene promoter methylation in Wilms' tumour and colorectal cancer. Oncogene 2002; 21: 7277-7282.
16. Ehrlich M, Jiang G, Fiala E, et al. Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene 2002; 21: 6694-6702.
17. Harada K, Toyooka S, Maitra A, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002; 21: 4345-4349.
18. Haruta M, Arai Y, Sugawara W, et al. Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities. Genes Chromosomes Cancer 2008; 47: 712-727.
19. Oue T, Fukuzawa M, Okita H, et al. Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol: A report from the JWiTS Group. Pediatr Surg Int 2009; 25: 923-929.
20. Ishiwata I, Ono I, Ishiwata C, et al. Carcinoembryonic proteins produced by Wilms' tumor cells in vitro and in vivo. Exp Pathol 1991; 41: 1-9.
21. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumor: Results from the first National Wilms' Tumor Study. Cancer 1978; 41: 1937-1948.
22. Japanese Pathological Society. Committee on histological classification of childhood tumors: Tumors of the kidney, 1st edition. Tokyo: Kanahara Shuppan; 2008.
23. Herman JG, Graff JR, Myöhänen S, et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
24. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: A high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000; 28: E32.
25. Nannya Y, Sanada S, Nakazaki K, et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005; 65: 6071-6079.
26. Yamamoto Y, Nannya Y, Kato M, et al. Highly sensitive method for genome wide detection of allelic composition in nonpaired, primary specimens by use of Affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 2007; 81: 114-126.
27. Furukawa S, Haruta M, Arai Y, et al. Yolk sac tumor but not seminoma or teratoma is associated with abnormal epigenetic reprogramming pathway and shows frequent hypermethylation of various tumor suppressor genes. Cancer Sci 2009; 100: 698-708.
28. Messahel B, Williams R, Ridolfi A, et al. Allele loss at 16q defines poorer prognosis Wilms tumor irrespective of treatment approach in the UKW1-3 clinical trials: A Children's Cancer and Leukemia Group (CCLG) study. Eur J Cancer 2009; 45: 819-826.
29. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancer. Cancer Res 2005; 65: 3497-3508.
30. Waber PG, Chen J, Nisen PD. Infrequency of ras, p53, WT1, or RB gene alterations in Wilms tumors. Cancer 1993; 72: 3732-3738.
31. Luo XN, Reddy JC, Yeyati PL, et al. The tumor suppressor gene WT1 inhibits ras-mediated transformation. Oncogene 1995; 11: 743-750.
32. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
33. Yang Q, Zage P, Kagan D, et al. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res 2004; 10: 8493-8500.